Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1501 of 5804
-
Can a 6-week online class for parents boost communication in toddlers with autism signs?
Symptom relief OngoingThe goal of this randomized control trial is to test the efficacy of the Social ABCs 6 week, group-based model using a virtual delivery platform. The Social ABCs is a caregiver-mediated early intervention program, aiming to increase child skills in directed, intentional vocalizat…
Phase: NA • Sponsor: Holland Bloorview Kids Rehabilitation Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Could a gentle zap to the ear supercharge OCD treatment?
Symptom relief Recruiting nowIn the proposed investigation, the investigator will develop pilot data for the use of tVNS (transcutaneous vagal nerve stimulation) to enhance efficacy of exposure and response prevention therapy (ERP) to improve treatment success in patients with OCD. This data will include tol…
Phase: NA • Sponsor: University of Florida • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
PRP shot after ACL tear may curb arthritis risk
Disease control Recruiting nowThe purpose of our study is to examine the effect of platelet-rich-plasma (PRP) injection on the short-term resolution of post-injury inflammation (biomarkers) and improvement in joint function in patients with acute ACL injury. This RCT has been powered based on the questionnair…
Phase: PHASE3 • Sponsor: Hospital for Special Surgery, New York • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug duo aims to shrink hard-to-treat colon cancer
Disease control OngoingThis trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could a diabetes pill protect your heart valve?
Disease control TerminatedThis is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms…
Phase: PHASE2, PHASE3 • Sponsor: REDNVIA Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy targets Hard-to-Treat GI cancers
Disease control Recruiting nowThis is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in patients with metastatic or unresectable gast…
Phase: PHASE1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Scientists hunt for genes behind rare COVID-19 vaccine reactions.
Knowledge-focused Recruiting nowVaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombo…
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New infusion could shield celiac patients from gluten accidents
Disease control CompletedThe main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease (CeD) on a gluten-free diet (GFD). Participants will receive TAK-101 and/or placebo through the vein on Day 1 and Day 8. All parti…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo therapy shows promise for rare blood cancer
Disease control OngoingThis phase II trial studies the effect of venetoclax and azacitidine in treating patients with therapy related or secondary myelodysplastic syndrome. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, s…
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Targeted PET scan spots cancer protein, guiding treatment
Diagnosis Recruiting nowThe objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.
Phase: NA • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
New back joint could replace fusion surgery
Disease control OngoingThis study is designed to collect safety and efficacy data on patients who plan to undergo a single-level total joint replacement of the lumbar spine using the MOTUS device (MOTUS Total Joint Replacement procedure) to demonstrate noninferiority to lumbar interbody fusion with res…
Phase: NA • Sponsor: 3Spine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug aims to restore joy in depressed patients
Symptom relief CompletedThe purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had a…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThe primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue unti…
Phase: PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo eye injection shows promise for Diabetes-Related vision loss
Disease control CompletedThis study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 followin…
Phase: PHASE1, PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Vitamin k pills could unclog arteries, new study hints
Disease control OngoingThe purpose of this study is to examine the effect of menaquinone-7 (MK-7) supplementation on cardiovascular, metabolic, and bone health.
Phase: NA • Sponsor: Bispebjerg Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug combo aims to tackle tough lymphoma
Disease control OngoingThe purpose of this study is to determine the correct dose and safety of combining two new cancer drugs, loncastuximab tesirine and venetoclax, as a treatment for relapsed or refractory B cell lymphoma.These drugs are used to treat some lymphomas, but have not yet been tested in …
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New immune therapy targets Hard-to-Treat multiple myeloma
Disease control OngoingThis phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for expression of the MUC1 protein. T-cells are infecti…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could a simple education program help people with bipolar disorder stay well longer?
Disease control CompletedStudy objectives: 1. To determine the effectiveness of the CaPE intervention compared to treatment as usual (TAU) in reducing the time to recurrence for people with bipolar disorder (BD) I/II, currently in remission in Pakistan 2. To determine the impact of the CaPE intervention…
Phase: NA • Sponsor: Pakistan Institute of Living and Learning • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental combo aims to boost immune attack on tough melanoma
Disease control OngoingActivation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes by DEC-C during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+ T-cells, NK cells) and reduce the frequency and activ…
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New cocktail of cancer drugs shows promise for tough lymphoma
Disease control OngoingThe primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the…
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC